Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences Statistics

Total Valuation

XBIO has a market cap or net worth of $7.47 million. The enterprise value is -$758,448.

Market Cap	7.47M
Enterprise Value	-758,448

Important Dates

The next estimated earnings date is Tuesday, May 12, 2026, after market close.

Earnings Date	May 12, 2026
Ex-Dividend Date	n/a

Share Statistics

XBIO has 2.29 million shares outstanding. The number of shares has increased by 10.40% in one year.

Current Share Class	2.29M
Shares Outstanding	2.29M
Shares Change (YoY)	+10.40%
Shares Change (QoQ)	+41.35%
Owned by Insiders (%)	3.80%
Owned by Institutions (%)	2.58%
Float	1.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.39
Forward PS	n/a
PB Ratio	0.96
P/TBV Ratio	0.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.32

Current Ratio	8.32
Quick Ratio	8.14
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -40.00% and return on invested capital (ROIC) is -26.44%.

Return on Equity (ROE)	-40.00%
Return on Assets (ROA)	-23.21%
Return on Invested Capital (ROIC)	-26.44%
Return on Capital Employed (ROCE)	-38.33%
Weighted Average Cost of Capital (WACC)	16.39%
Revenue Per Employee	$1.49M
Profits Per Employee	-$1.34M
Employee Count	2
Asset Turnover	0.39
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +40.22% in the last 52 weeks. The beta is 2.21, so XBIO's price volatility has been higher than the market average.

Beta (5Y)	2.21
52-Week Price Change	+40.22%
50-Day Moving Average	2.63
200-Day Moving Average	2.99
Relative Strength Index (RSI)	60.94
Average Volume (20 Days)	16,649

Short Selling Information

The latest short interest is 20,598, so 0.90% of the outstanding shares have been sold short.

Short Interest	20,598
Short Previous Month	41,648
Short % of Shares Out	0.90%
Short % of Float	1.10%
Short Ratio (days to cover)	1.83

Income Statement

In the last 12 months, XBIO had revenue of $2.98 million and -$2.68 million in losses. Loss per share was -$1.58.

Revenue	2.98M
Gross Profit	2.98M
Operating Income	-2.83M
Pretax Income	-2.68M
Net Income	-2.68M
EBITDA	n/a
EBIT	-2.83M
Loss Per Share	-$1.58

Balance Sheet

The company has $7.88 million in cash and n/a in debt, with a net cash position of $7.88 million or $3.44 per share.

Cash & Cash Equivalents	7.88M
Total Debt	n/a
Net Cash	7.88M
Net Cash Per Share	$3.44
Equity (Book Value)	7.40M
Book Value Per Share	3.23
Working Capital	7.08M

Cash Flow

Operating Cash Flow	-2.29M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	-2.29M
FCF Per Share	-$1.00

Margins

Gross margin is 100.00%, with operating and profit margins of -95.23% and -90.07%.

Gross Margin	100.00%
Operating Margin	-95.23%
Pretax Margin	-90.07%
Profit Margin	-90.07%
EBITDA Margin	n/a
EBIT Margin	-95.23%
FCF Margin	n/a

Dividends & Yields

XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.40%
Shareholder Yield	-10.40%
Earnings Yield	-37.63%
FCF Yield	-32.09%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	May 15, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

XBIO has an Altman Z-Score of -29.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-29.73
Piotroski F-Score	3